27 Result(s)

Article

Frequency and Severity of Hypoglycemia Under Conditions of Increased Hypoglycemic Risk with Insulin Efsitora Alfa Versus Insulin Glargine Treatment in Participants with Type 2 Diabetes

Insulin efsitora alfa (efsitora) is a basal insulin with a flat pharmacokinetic profile and long half-life, enabling weekly dosing. These attributes may provide stable glucose levels. This exploratory phase 1 ...

Tim Heise, Grit Andersen, Edward J. Pratt, Jennifer Leohr… in Diabetes Therapy (2024)

Article

Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus

This study was performed to satisfy a US Food and Drug Administration post-marketing requirement to compare the dose responses for Technosphere^® Insulin (TI; MannKind Corporation, Westlake Village, CA, USA) and s...

Marshall Grant, Tim Heise, Robert Baughman in Clinical Pharmacokinetics (2022)

Article

Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesity

The study characterizes safety, tolerability, pharmacokinetic and pharmacodynamic profiles of single rising doses of the 11beta-hydroxysteroid dehydrogenase-1 (11beta-HSD1) inhibitor BI 187004 in healthy men w...

Susanna Bianzano, Tim Heise, Arvid Jungnik… in Clinical Diabetes and Endocrinology (2021)

Article

Glucose management for exercise using continuous glucose monitoring: should sex and prandial state be additional considerations? Reply to Yardley JE and Sigal RJ [letter]

Othmar Moser, Michael C. Riddell, Max L. Eckstein, Peter Adolfsson… in Diabetologia (2021)

Article

Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog^® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study

Ultra rapid lispro (URLi) is a novel insulin lispro formulation developed to more closely match physiological insulin secretion and improve postprandial glucose control. This study compared the insulin lispro ...

Jennifer Leohr, Mary Anne Dellva, David E. Coutant… in Clinical Pharmacokinetics (2020)

Article

Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA)

Physical exercise is an important component in the management of type 1 diabetes across the lifespan. Yet, acute exercise increases the risk of dysglycaemia, and the direction of glycaemic excursions depends, ...

Othmar Moser, Michael C. Riddell, Max L. Eckstein, Peter Adolfsson… in Diabetologia (2020)

Article

Costs and its drivers for diabetes mellitus type 2 patients in France and Germany: a systematic review of economic studies

Type 2 diabetes represents an increasingly critical challenge for health policy worldwide. It absorbs massive resources from both patients and national economies to sustain direct costs of the treatment of typ...

Constance Stegbauer, Camilla Falivena, Ariadna Moreno… in BMC Health Services Research (2020)

Article

Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences

Fast-acting insulin aspart (faster aspart) is insulin aspart (IAsp) with two added excipients, l-arginine and niacinamide, to ensure formulation stability with accelerated initial absorption after subcutaneous ad...

Hanne Haahr, Tim Heise in Clinical Pharmacokinetics (2020)

Article

The Effect of Food Intake on the Pharmacokinetics of Oral Basal Insulin: A Randomised Crossover Trial in Healthy Male Subjects

Oral insulin 338 is a novel tablet formulation of a long-acting basal insulin. This randomised, open-label, four-period crossover trial investigated the effect of timing of food intake on the single-dose pharm...

Inge B. Halberg, Karsten Lyby, Karsten Wassermann, Tim Heise… in Clinical Pharmacokinetics (2019)

Article

Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus

Fast-acting insulin aspart (faster aspart) is an ultra-fast-acting formulation of insulin aspart (IAsp). This post hoc analysis investigated the pharmacokinetics of faster aspart versus IAsp, measured as free ...

Hanne Haahr, Thomas R. Pieber, Chantal Mathieu, Theis Gondolf… in Clinical Pharmacokinetics (2019)

Article

Bed rest and resistive vibration exercise unveil novel links between skeletal muscle mitochondrial function and insulin resistance

Physical inactivity has broad implications for human disease including insulin resistance, sarcopenia and obesity. The present study tested the hypothesis that (1) impaired mitochondrial respiration is linked ...

Helena C. Kenny, Floriane Rudwill, Laura Breen, Michele Salanova… in Diabetologia (2017)

Article

Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus

Absorption of current rapid-acting insulins is too slow for patients with diabetes mellitus to achieve optimal postprandial glucose control. Faster-acting insulin aspart (faster aspart) is insulin aspart in a ...

Tim Heise, Kirstine Stender-Petersen, Ulrike Hövelmann… in Clinical Pharmacokinetics (2017)

Article

Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions

Fast-acting insulin aspart (faster aspart) is insulin aspart set in a new formulation with faster initial absorption after subcutaneous administration. This study investigated the pharmacokinetic properties, i...

Ulrike Hövelmann, Tim Heise, Leszek Nosek… in Clinical Drug Investigation (2017)

Article

A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes

Fast-acting insulin aspart (faster aspart) is insulin aspart (IAsp) in a new formulation aiming to mimic the fast endogenous prandial insulin release more closely than currently available insulin products. In ...

Tim Heise, Thomas R. Pieber, Thomas Danne, Lars Erichsen… in Clinical Pharmacokinetics (2017)

Article

A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use

Insulin degludec/insulin aspart (IDegAsp; 70 % IDeg and 30 % IAsp) is a soluble combination of two individual insulin analogues in one product, designed to provide mealtime glycaemic control due to the IAsp co...

Hanne Haahr, Edmond G. Fita, Tim Heise in Clinical Pharmacokinetics (2017)

Article

A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus

Due to population aging, an increasing number of elderly patients with diabetes use insulin. It is therefore important to investigate the characteristics of new insulins in this population. Faster-acting insul...

Tim Heise, Ulrike Hövelmann, Eric Zijlstra, Kirstine Stender-Petersen… in Drugs & Aging (2017)

Article

Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes

Sodium glucose co-transporter 2 (SGLT2) inhibitors lower glycaemia by inducing glycosuria, but raise endogenous glucose production (EGP). Metformin lowers glycaemia mainly by suppressing EGP. We compared the e...

Elza Muscelli, Brenno Astiarraga, Elisabetta Barsotti, Andrea Mari… in Diabetologia (2016)

Article

NMDA receptor dependent anti-diabetic effects

Jan Marquard, Silke Otter, Alena Welters… in Molecular and Cellular Pediatrics (2014)